Patents Examined by Samuel C. Woolwine
-
Patent number: 11965217Abstract: A method and a kit for detecting Mycobacterium tuberculosis are provided. The method includes a step of performing a nested qPCR assay to a specimen. The nested qPCR assay includes a first round of amplification using external primers and a second round of amplification using internal primers and a probe. The external primers have sequences of SEQ ID NOs. 1 and 2, and the internal primers and the probe have sequences of SEQ ID NOs. 3 to 5.Type: GrantFiled: May 24, 2021Date of Patent: April 23, 2024Assignee: DELTA ELECTRONICS, INC.Inventors: Yi-Chen Li, Chih-Cheng Tsou, Min-Hsien Wu, Hsin-Yao Wang, Chien-Ru Lin
-
Patent number: 11953495Abstract: Disclosed are a molecule detection unit, a chip and a preparation method. The molecule detection unit includes a single-hole liquid storage cavity, a liquid resistance flow channel, a buffer flow channel, a sensing electrode, a substrate, a first structural layer, a second structural layer and a sample flow channel. The first structural layer is arranged on the top of the substrate; the single-hole liquid storage cavity and the buffer flow channel are arranged in the first structural layer and are independent of each other; the liquid resistance flow channel is arranged in the first structural layer, and two ends of the liquid resistance flow channel are respectively communicated with the single-hole liquid storage cavity and the buffer flow channel; the second structural layer is arranged on the top of the first structural layer and covers the top of the buffer flow channel.Type: GrantFiled: September 20, 2023Date of Patent: April 9, 2024Assignee: Beijing Qitan Tech Co., Ltd.Inventors: Yuan Wang, Xiaoxiang Xia, Lu Song
-
Patent number: 11952622Abstract: Methods for analyzing DNA-containing samples are provided. The methods can comprise isolating a single genomic equivalent of DNA from the DNA-containing sample to provide a single isolated DNA molecule. The single isolated DNA molecule can be subjected to amplification conditions in the presence of one or more sets of unique molecularly tagged primers to provide one or more amplicons. Any spurious allelic sequences generated during the amplification process are tagged with an identical molecular tag. The methods can also include a step of determining the sequence of the one or more amplicons, in which the majority sequence for each code is selected as the sequence of the single original encapsulated target. The DNA-containing sample can be a forensic sample (e.g., mixed contributor sample), a fetal genetic screening sample, or a biological cell.Type: GrantFiled: July 15, 2014Date of Patent: April 9, 2024Assignee: The Johns Hopkins UniversityInventors: Andrew B. Feldman, Jeffrey S. Lin, David Weitz, Assaf Rotem
-
Patent number: 11946067Abstract: The present invention concerns a genetic tool comprising at least two distinct nucleic acids optimized to facilitate the transformation and modification by homologous recombination of a bacterium of the genus Clostridium, typically a solventogenic bacterium.Type: GrantFiled: May 24, 2019Date of Patent: April 2, 2024Assignee: IFP ENERGIES NOUVELLESInventors: Nicolas Lopes Ferreira, François Wasels, Gwladys Chartier
-
Patent number: 11946099Abstract: The invention comprises a method of amplifying nucleic acids by primer extension with reduced formation of primer-primer byproducts.Type: GrantFiled: February 23, 2021Date of Patent: April 2, 2024Assignee: ROCHE SEQUENCING SOLUTIONS, INC.Inventor: Brian Godwin
-
Patent number: 11939604Abstract: A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cash which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualisation, transcriptional activation or repression.Type: GrantFiled: February 18, 2021Date of Patent: March 26, 2024Assignee: Caribou Biosciences, Inc.Inventors: Stan Johan Jozef Brouns, John van der Oost
-
Patent number: 11920151Abstract: Provided are: a composition for DNA double-strand breaks (DSBs), comprising (1) a cytosine deaminase and an inactivated target-specific endonuclease, (2) a guide RNA, and (3) a uracil-specific excision reagent (USER); a method for producing DNA double-strand breaks by means of a cytosine deaminase using the composition; a method for analyzing a DNA nucleic acid sequence to which base editing has been introduced by means of a cytosine deaminase; and a method for identifying (or measuring or detecting) base editing, base editing efficiency at an on-target site, an off-target site, and/or target specificity by means of a cytosine deaminase.Type: GrantFiled: September 13, 2017Date of Patent: March 5, 2024Assignees: TOOLGEN INCORPORATED, SEOUL NATIONAL UNIVERSITY R&Db FOUNDATION, INSTITUTE FOR BASIC SCIENCEInventor: Daesik Kim
-
Patent number: 11913081Abstract: A proximity dependent split T7 RNAP (RNA polymerase) sensor using continuous molecular evolution is described. The versatility of the platform is described by creating robust light and small molecule-responsive genetic sensors. The activity-responsive RNAP platform dramatically simplifies and expands genetic circuit creation, and opens new opportunities in protein engineering, synthetic biology, and bioengineering.Type: GrantFiled: June 6, 2017Date of Patent: February 27, 2024Assignee: The University of ChicagoInventors: Bryan C. Dickinson, Jinyue Pu, Julia Zinkus
-
Patent number: 11913017Abstract: A guide RNA comprising: a gRNA spacer sequence at the 5? end of the guide RNA, wherein the spacer sequence is complementary to a target gene, a scaffold sequence that binds to Cas9, and an RNA capture and sequencing domain comprising: a barcode sequence, and a primer binding sequence; nucleic acids and vectors encoding the guide RNA; cells expressing the guide RNA; and a library comprising a plurality of guide RNAs. Also disclosed are methods of introducing a genetic perturbation into a cell, methods of assessing an effect of at least one genetic perturbation on RNA expression in a cell, methods of identifying nucleic acid sequences associated with a disease state and a method of identifying candidate therapeutic agents.Type: GrantFiled: June 28, 2017Date of Patent: February 27, 2024Assignee: The Regents of the University of CaliforniaInventors: Kun Zhang, Prashant Mali, Yan Wu, Dongxin Zhao
-
Patent number: 11915795Abstract: Methods are provided for nucleic acid analysis via a platform which incorporates a digital sample partitioning platform such as a microfluidic chip or digital droplet platform and instrumentation to accomplish universal amplification, High Resolution Melting (HRM), and machine learning within reactions simultaneously.Type: GrantFiled: December 22, 2017Date of Patent: February 27, 2024Assignee: The Regents of the University of CaliforniaInventors: Stephanie I. Fraley, Sinead Charpentier, Daniel Ortiz Velez, Mridu Sinha, Benjamin Albert Yang
-
Patent number: 11905549Abstract: Provided is a method of modifying a target site in the genome of a eukaryotic cell, the method comprising: (1) a step of introducing into the cell, introduction nucleic acids comprising (a) a template nucleic acid comprising a nucleic acid sequence encoding an RNA-guided nuclease, (b) a template nucleic acid comprising a nucleic acid sequence encoding a guide RNA, or a guide RNA, and (c) a template nucleic acid comprising a nucleic acid sequence encoding a selectable marker; and (2) a step of selecting a cell expressing the selectable marker, wherein the number of moles (C) of (c) the template nucleic acid comprising a nucleic acid sequence encoding a selectable marker, subjected to the step (1), is smaller than any of the number of moles (A) of (a) the template nucleic acid comprising a nucleic acid sequence encoding an RNA-guided nuclease and the number of moles (B) of (b) the template nucleic acid comprising a nucleic acid sequence encoding a guide RNA, or the guide RNA.Type: GrantFiled: August 9, 2017Date of Patent: February 20, 2024Assignee: GENAHEAD BIO, INC.Inventor: Tsukasa Sugo
-
Patent number: 11906511Abstract: The present invention provides compositions and methods for detecting exhausted T cells in a subject. The present invention also provides methods for treating a subject having a disease characterized by the presence of exhausted T cells or certain subpopulations thereof.Type: GrantFiled: October 26, 2018Date of Patent: February 20, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: E. John Wherry, Bertram Bengsch, Omar Khan, Jennifer Wu, Josephine Giles
-
Patent number: 11905554Abstract: A sequencing primer set comprising a universal upstream primer, a universal downstream primer and a downstream primer in rich of promoter; wherein the universal upstream primer has a sequence of: 5?-TBarcodeCAAAXXXXNNN-3?; the universal downstream primer has a sequence of: 5?-GACTGCGTACGZZZZNNN-3?(SEQ ID No. 9); the downstream primer in rich of promoter has a sequence of: 5?-GACTGCGTACYYNCTATA-3?(SEQ ID No. 7).Type: GrantFiled: September 25, 2020Date of Patent: February 20, 2024Inventors: Zhiqiang Xia, Meiling Zou, Wenquan Wang
-
Patent number: 11896678Abstract: The present disclosure provides compositions and methods for the treatment of PPARG activated cancer. For example, the present disclosure provides PPARG signaling modulators for the treatment of bladder cancer. In particular, therapeutic and/or prophylactic compositions and uses of PPARG inverse-agonists are described.Type: GrantFiled: March 28, 2018Date of Patent: February 13, 2024Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.Inventors: Jonathan Goldstein, Matthew Meyerson, Craig Strathdee
-
Patent number: 11898205Abstract: This disclosure relates to methods for increasing capture efficiency of a spatial array using rolling circle amplification of a padlock probe that hybridizes to a capture probe. Also provided are methods for using such spatial arrays to detect a biological analyte in a biological sample.Type: GrantFiled: February 2, 2021Date of Patent: February 13, 2024Assignee: 10x Genomics, Inc.Inventor: Felice Alessio Bava
-
Patent number: 11891599Abstract: Disclosed is a method for the recovery of nucleic acids from a solid support, the method comprising the steps, in any suitable order, of: a) providing a solid support at least a region of which is absorbent and impregnated with a chaotropic agent; b) combining a biological sample, possibly including nucleic acids, with the region; c) washing the region in a washing buffer solution; d) simultaneously heating and agitating the region in a further buffer solution; e) separating the region from the further buffer solution; f) extracting at least a portion of any remaining further buffer solution from the region to provide an extracted buffer solution; g) combining the further buffer solution and the extracted buffer solution portion; and h) subsequently processing the combined buffer solutions in order to amplify any nucleic acids in said combined solution. Hardware suitable for implementing the above method and a kit of parts is disclosed also.Type: GrantFiled: May 18, 2018Date of Patent: February 6, 2024Assignee: QIAGEN Healthcare Biotechnologies Systems GmbHInventors: Paresh Lakhubhai Patel, Lin Chen, Melissa Schwandt, Koya Reams, Thomas Hansen
-
Patent number: 11883470Abstract: A synthetic or recombinant human lecithin cholesterol acyltransferase (LCAT) variant is provided which comprises an LCAT enzyme having a substitution at position 114 based on the residue numbering of wild-type (WT) human LCAT [SEQ ID NO:1], wherein said variant is characterized by one or more of: (i) an esterification rate higher than the esterification rate of WT human LCAT; and/or (ii) an association with higher density lipoprotein levels as compared to subjects having WT LCAT. Also provided are vectors encoding the variant, compositions containing same, and methods of using the variant proteins and vectors for treatment of a variety of disorders associated with defective wt LCAT.Type: GrantFiled: July 24, 2017Date of Patent: January 30, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Daniel Rader, Devin Christopher, Anna P. Tretiakova
-
Patent number: 11879134Abstract: A native Type I-B and heterologous Type II Clustered Regularly-Interspaced Short Palindromic Repeat/cas systems were developed and characterize to improve the ability to engineer C. thermocellum and other thermophilic microbes. The native Type I-B system was engineered for genome editing. For the Type I-B system, an engineered strain, termed LL1586, yielded 40% genome editing efficiency at the pyrF locus. When recombineering machinery was expressed the efficiency was increased to 71%. For the Type II GeoCas9 system, 12.5% genome editing efficiency was observed. When recombineering machinery was expressed, this increased to 94%. By combining the thermophilic CRISPR system (either Type I-B or Type II) with the recombinases, a new tool was developed that allows for efficient CRISPR editing. The tools provided herein enable CRISPR technologies to better engineer C. thermocellum, including engineering C. thermocellum for both increased lignocellulose degradation and biofuel production.Type: GrantFiled: September 4, 2020Date of Patent: January 23, 2024Assignee: The Regents of the University of Colorado, a body corporateInventors: Carrie Eckert, Julie E. Walker
-
Patent number: 11873535Abstract: Described herein are methods and kits for authentication of botanical DNA fragments isolated from processed botanical products, including dietary supplements or nutraceutical compositions including botanical extracts.Type: GrantFiled: July 27, 2018Date of Patent: January 16, 2024Assignee: HERBALIFE INTERNATIONAL OF AMERICA, INC.Inventors: Zhengfei Lu, Silva Babajanian, Yanjun Zhang, Peter Chang, Gary Swanson, Maria Rubinsky
-
Patent number: 11873485Abstract: Programmable guide RNAs (gRNAs) play a central role in the CRISPR revolution sweeping biology and medicine by directing the function of a Cas protein effector to a target gene of choice. To achieve programmable control over regulatory scope, the activity of a conditional guide RNA (cgRNA) depends on the presence or absence of an RNA trigger, allowing for cell-selective regulation of CRISPR/Cas function. Unlike a standard gRNA, a cgRNA is programmable at multiple levels, with the target-binding sequence controlling the target of Cas activity (edit, silence, induce, or bind a gene of choice) and the trigger binding sequence controlling the scope of Cas activity. cgRNA mechanisms that are allosteric allow for independent design of the target and trigger sequences, providing the flexibility to select the regulatory target and scope independently.Type: GrantFiled: January 25, 2022Date of Patent: January 16, 2024Assignee: California Institute of TechnologyInventors: Lisa Hochrein, Mikhail H. Hanewich-Hollatz, Zhewei Chen, Heyun Li, Shashank Gandhi, Marianne Bronner, Niles A. Pierce